Press coverage about Momenta Pharmaceuticals (NASDAQ:MNTA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.3983953774119 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Momenta Pharmaceuticals, Inc. (MNTA) Director Sells $292,752.00 in Stock (americanbankingnews.com)
- Momenta Up on FDA’s Amendment of McPherson Compliance Status (finance.yahoo.com)
- Momenta Pharmaceuticals (MNTA) versus Prana Biotechnology (PRAN) Head-To-Head Contrast (americanbankingnews.com)
- Momenta Up on FDA's Amendment of McPherson Compliance Status (finance.yahoo.com)
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down $0.80 during mid-day trading on Friday, hitting $15.90. The stock had a trading volume of 544,327 shares, compared to its average volume of 995,598. The stock has a market capitalization of $1,298.58 and a price-to-earnings ratio of -19.88. Momenta Pharmaceuticals has a 1-year low of $11.85 and a 1-year high of $19.60.
MNTA has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Robert W. Baird downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from $22.00 to $15.00 in a research report on Friday, October 6th. Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, ValuEngine downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and ten have given a hold rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $15.30.
In other news, CEO Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total transaction of $54,948.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Elizabeth Stoner sold 16,264 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $18.00, for a total value of $292,752.00. Following the transaction, the director now directly owns 32,440 shares of the company’s stock, valued at $583,920. The disclosure for this sale can be found here. Insiders sold 65,769 shares of company stock valued at $978,675 over the last three months. 4.40% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/2018/02/02/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-momenta-pharmaceuticals-mnta-stock-price/1824699.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.